Table 10.
Health outcomes breakdown per 1,000 for each prophylaxis strategy - eTKR population.
| Intervention | Short-term health outcomes [n (95% CI)] | Long-term health outcomes [n(95% CI)] | |||||||
|---|---|---|---|---|---|---|---|---|---|
| Symptomatic DVT | Sympt proximal DVT | Asymptomatic DVT | PE | Total VTE | Surgical site bleeding | Total deaths | PTS | CTEPH | |
| LMWH (std,std) + AES | 6 (5 to 8) |
1 (0 to 2) |
134 (132 to 136) |
4 (4 to 5) |
144 (143 to 146) |
9 (1 to 32) |
1 (0 to 2) |
8 (6 to 11) |
0 (0 to 0) |
| Fondaparinux+ AES | 6 (2 to 13) |
1 (0 to 3) |
121 (36 to 261) |
10 (2 to 25) |
136 (46 to 284) |
79 (2 to 411) |
2 (0 to 6) |
8 (3 to 16) |
0 (0 to 1) |
| Foot pump + AES | 9 (4 to 15) |
2 (0 to 4) |
181 (91 to 311) |
6 (3 to 11) |
195 (101 to 333) |
12 (1 to 51) |
1 (0 to 3) |
10 (5 to 19) |
0 (0 to 0) |
| IPCD | 10 (3 to 19) |
2 (0 to 5) |
202 (66 to 405) |
19 (0 to 175) |
230 (71 to 495) |
12 (1 to 51) |
4 (0 to 35) |
13 (4 to 38) |
1 (0 to 5) |
| Foot pump | 4 (0 to 12) |
1 (0 to 3) |
79 (11 to 243) |
3 (0 to 9) |
85 (14 to 259) |
12 (1 to 51) |
1 (0 to 2) |
5 (1 to 14) |
0 (0 to 0) |
| AES | 13 (6 to 22) |
3 (1 to 6) |
285 (144 to 465) |
24 (0 to 203) |
323 (158 to 567) |
12 (1 to 51) |
5 (0 to 39) |
18 (8 to 48) |
1 (0 to 6) |
| LMWH (std,std) | 4 (1 to 9) |
1 (0 to 2) |
89 (30 to 195) |
21 (0 to 232) |
114 (33 to 337) |
9 (1 to 32) |
4 (0 to 44) |
8 (2 to 37) |
1 (0 to 7) |
| LMWH (std,extd) | 4 (1 to 10) |
1 (0 to 2) |
76 (18 to 204) |
8 (0 to 49) |
88 (19 to 238) |
10 (0 to 68) |
2 (0 to 10) |
5 (1 to 16) |
0 (0 to 1) |
| Aspirin | 7 (2 to 17) |
1 (0 to 4) |
149 (39 to 367) |
5 (1 to 12) |
160 (45 to 390) |
9 (8 to 11) |
1 (0 to 3) |
9 (2 to 20) |
0 (0 to 0) |
| Dabigatran | 4 (1 to 10) |
1 (0 to 2) |
88 (27 to 199) |
51 (0 to 644) |
142 (32 to 722) |
11 (1 to 45) |
11 (0 to 127) |
12 (2 to 98) |
2 (0 to 19) |
| Apixaban | 2 (1 to 6) |
0 (0 to 1) |
51 (15 to 121) |
44 (0 to 568) |
97 (18 to 606) |
8 (0 to 35) |
9 (0 to 102) |
9 (1 to 85) |
1 (0 to 16) |
| Rivaroxaban | 2 (1 to 5) |
0 (0 to 1) |
42 (11 to 104) |
16 (0 to 163) |
60 (14 to 211) |
16 (1 to 67) |
3 (0 to 34) |
4 (1 to 24) |
0 (0 to 5) |
| No prophylaxis | 15 (6 to 27) |
3 (1 to 7) |
328 (132 to 565) |
41 (0 to 429) |
385 (151 to 781) |
12 (1 to 51) |
8 (0 to 87) |
23 (7 to 81) |
1 (0 to 13) |
AES, anti-embolism stockings; CTEPH, chronic thromboembolic pulmonary hypertension; DVT, deep vein thrombosis; eTKR, elective total knee replacement; extd, extended; IPCD, intermittent pneumatic compression devices; LMWH, low molecular weight heparin; PE, pulmonary embolism; PTS, post thrombotic syndrome; std, standard; VTE, venous thromboembolism.